Item 8.01. Other Events
On June 25, 2009, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing the initiation of a home care treatment program for patients enrolled in the Company's phase III extension trial of plant-cell expressed recombinant glucocerebrosidase (prGCD), the Company's lead product candidate. The phase III extension trial is a follow-on study to the Company's on-going pivotal phase III clinical trial, which is evaluating the safety and efficacy of prGCD in treatment-naive patients of Gaucher disease, a lysosomal storage disorder in humans. A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits

99.1 Press release dated June 25, 2009.

---